The estimated Net Worth of Alison Oneill is at least $165 millier dollars as of 1 August 2023. Alison Oneill owns over 7,042 units of Surface Oncology Inc stock worth over $60,654 and over the last 5 years Alison sold SURF stock worth over $104,631.
Alison has made over 3 trades of the Surface Oncology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Alison sold 7,042 units of SURF stock worth $6,619 on 1 August 2023.
The largest trade Alison's ever made was selling 14,809 units of Surface Oncology Inc stock on 1 March 2020 worth over $90,335. On average, Alison trades about 3,759 units every 178 days since 2020. As of 1 August 2023 Alison still owns at least 56,686 units of Surface Oncology Inc stock.
You can see the complete history of Alison Oneill stock trades at the bottom of the page.
Alison's mailing address filed with the SEC is C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.
surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww
Surface Oncology Inc executives and other stock owners filed with the SEC include: